BSX Q3 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Boston Scientific Corporation (BSX)
Last boston scientific corporation earnings: 4/29 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.bostonscientific.com
Company Research
Source: Globe and Mail, The
Executive Vice President and Chief Financial Officer — Jonathan D. Monson Chief Medical Officer — Dr. Ken Stein Vice President, Investor Relations — Lauren Tengler Takeaways Organic revenue growth -- 15.3% driven by broad performance, outpacing the 12%-14% guidance range. Adjusted EPS -- $0.75, up 19%, surpassing the $0.70-$0.72 guidance range. Adjusted operating margin -- 28%, expanding 80 basis points versus prior year due to mix and volume. Gross margin -- 71%, rising 60 basis points, with mix benefits from electrophysiology and WATCHMAN outweighing tariff costs. Fiscal Q4 and full-year 2025 organic revenue guidance (period ending Dec. 31, 2025) -- Q4: 11%-13%; full year raised to 15.5%. Fiscal Q4 and full-year adjusted EPS guidance (period ending Dec. 31, 2025) -- Q4: $0.77-$0.79; full year raised to $3.02-$3.04, representing growth of 20%-21%. Reported revenue -- $5.065 billion, up 20.3%, with a $38 million positive impact from foreign exchange. Free cash f
Show less
Read more
Impact Snapshot
Event Time:
BSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSX alerts
High impacting Boston Scientific Corporation news events
Weekly update
A roundup of the hottest topics
BSX
News
- Boston Scientific forecasts 2026 organic growth of 6.5% to 8% amid revised outlook for EP and WATCHMAN [Seeking Alpha]Seeking Alpha
- Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- BSX Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Boston Scientific (NYSE:BSX) Surprises With Q1 CY2026 Sales [Yahoo! Finance]Yahoo! Finance
- Boston Scientific (BSX) had its price target lowered by Barclays PLC from $124.00 to $100.00. They now have an "overweight" rating on the stock.MarketBeat
BSX
Earnings
- 4/22/26 - In-Line
BSX
Sec Filings
- 4/22/26 - Form 8-K
- 4/2/26 - Form EFFECT
- 4/1/26 - Form 424B3
- BSX's page on the SEC website